Citations

Mayo Clinic

Showing 10 of 108585 citations.

Characterizing Pre-headache (Prodrome) Features of Migraine Attacks: Results From the CaMEO Study (S4.004)
Fanning, Kristina M. , Lama, Janette Contreras‐De, Jordan, Brittany L., Reed, Michael L. , Buse, Dawn C. , Schwedt, Todd J. , Nahas, Stephanie J. , Jordan, Brittany, Lipton, Richard B.

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1208 Get It

Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a Real-World Evidence Study (S1.008)
Ben‐Joseph, Rami , Saad, Ragy , Black, Jed , Dabrowski, Elizabeth , Gallucci, Sophia, Taylor, Ben , Somers, Virend K.

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1203 Get It

Neurostimulation in People with Drug-Resistant Epilepsy: Systematic Review and Meta-Analysis from the ILAE Surgical Therapies Commission (P7-8.001)
Dansereau, Bénédicte, Touma, Lahoud , Chan, Alvin Y. , Braun, Kees P. J. , Vadera, Sumeet, Jetté, Nathalie , Kwon, Churl-Su , Friedman, Daniel, Jehi, Lara , Rolston, John D. , Wong‐Kisiel, Lily C. , Englot, Dario J. , Keezer, Mark R.

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1145 Get It

Multi-center, Randomized, Double-blinded Assessment of TERIFLUNOMIDE (Aubagio®) in Extending the Time to the First Attack in Radiologically Isolated Syndrome: Baseline Characteristics of the TERIS Study. (P5-4.011)
Mondot, Lydiane, Papeix, Anne Caroline, Labauge, Pierre , Dubief, Françoise Durand, Page, Emmanuelle Le , Terzi, Murat , Derache, Nathalie, Bourre, Bertrand , Karabudak, Rana , Wiertlewski, Sandrine, Turan, Ömer Faruk , Kantarci, Orhun H. , Pelletier, Daniel, Lebrun‐Frénay, Christine , Landes-Château, Cassandre , Sıva, Aksel , Sormani, Maria Pia , Mondot, Lydiane , Vermersch, Patrick , Papeix, Caroline , Thouvenot, Éric , Efendi, Hüsnü , Bourre, Bertrand , Hoepner, Robert , Seze, Jerome De , Ciron, Jonathan , Clavelou, Pierre , Yüceyar, Nur , Cohen, Mikaël , Okuda, Darin T.

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1116 Get It

Normative Values for Sudomotor Axon Reflex Testing using QSWEAT™ (P1.282)
Sletten, David M., Grandinetti, Andrew, Weigand, Stephen D. , Gehrking, Tonette L., Gehrking, Jade A., Low, Phillip A. , Singer, Wolfgang

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p1.282 Get It

Challenges in the Care of Patients with AKI Receiving Outpatient Dialysis: AKINow Recovery Workgroup Report
Neyra, Javier A. , Gewin, Leslie S. , Ng, Jia Hwei , Frazee, Erin N. , Freshly, Bonnie, Willett, Jeff, Abdel‐Rahman, Emaad M. , Kwong, Yuenting Diana , Silver, Samuel A. , Gewin, Leslie , Ng, Jia H , Kwong, Yuenting D , Silver, Samuel A , Cerdá, Jorge , Vijayan, Anitha , Abdel-Rahman, Emaad M , McCoy, Ian E. , Cerdá, Jorge , Vijayan, Anitha

Kidney360 | December 6, 2023 | Volume: 5 | Issue: 2 | Pages: 274-284

10.34067/kid.0000000000000332 | PMID 38055734 Get It

Background Up to one third of survivors of AKI that required dialysis (AKI-D) during hospitalization remain dialysis dependent at hospital discharge. Of these, 20%–60%, depending on the clinical setting, eventually recover enough kidney function to stop dialysis, and the remainder progress to ESKD. Methods To describe the challenges facing those still receiving dialysis on discharge, the AKINow Committee conducted a group discussion comprising 59 participants, including physicians, advanced practitioners, nurses, pharmacists, and patients. The discussion was framed by a patient who described gaps in care delivery at different transition points and miscommunication between care team members and the patient. Results Group discussions collected patient perspectives of ( 1 ) being often scared and uncertain about what is happening to and around them and ( 2 ) the importance of effective and timely communication, a comfortable physical setting, and attentive and caring health care providers for a quality health care experience. Provider perspectives included ( 1 ) the recognition of the lack of evidence-based practices and quality indicators, the significant variability in current care models, and the uncertain reimbursement incentives focused on kidney recovery and ( 2 ) the urgency to address communication barriers among hospital providers and outpatient facilities. Conclusions The workgroup identified key areas for future research and policy change to ( 1 ) improve communication among hospital providers, dialysis units, and patients/care partners; ( 2 ) develop tools for risk classification, subphenotyping, and augmented clinical decision support; ( 3 ) improve education to providers, staff, and patients/care partners; ( 4 ) identify best practices to improve relevant outcomes; ( 5 ) validate quality indicators; and ( 6 ) assess the effect of social determinants of health on outcomes. We urge all stakeholders involved in the process of AKI-D care to align goals and work together to fill knowledge gaps and optimize the care to this highly vulnerable patient population.
Chimeric antigen receptor and bispecific T‐cell engager therapies in multiple myeloma patients with prior allogeneic transplantation
Hammons, Lindsay , Haider, Shabi , Portuguese, Andrew J. , Banerjee, Rahul , Pasquini, Marcelo C. , Chhabra, Saurabh , Radhakrishnan, Sabarinath Venniyil , Mohan, Meera , Narra, Ravi , Shah, Nirav N. , D’Souza, Anita , Dhakal, Binod , Pasquini, Marcelo , Chhabra, Saurabh , Mohan, Meera , Shah, Nirav N , Hamadani, Mehdi , D'Souza, Anita , Dhakal, Binod , Banerjee, Rahul , Portuguese, Andrew J , Szabó, Anikó , Dong, Jing , Janz, Siegfried , Hamadani, Mehdi , Hari, Parameswaran

British Journal of Haematology | December 6, 2023 | Volume: 204 | Issue: 3 | Pages: 887-891

10.1111/bjh.19244 | PMID 38054558 Get It

Summary Chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific T‐cell engagers (BsAb) have emerged as promising immunotherapeutic modalities in patients with relapsed and/or refractory multiple myeloma (RRMM). However, there is limited data on the safety and efficacy of CAR‐T and BsAb therapies in MM patients with a prior history of allogeneic transplantation (allo‐HCT). Thirty‐three MM patients with prior allo‐HCT received CAR‐T ( n = 24) or BsAb ( n = 9) therapy. CAR‐T therapy demonstrated an ORR of 92% (67% ≥ CR), and 73% were MRD negative. BsAb therapy resulted in an ORR of 44% (44% ≥ CR) and 44% MRD negative. Safety analysis showed grade ≥3 AEs in 92% of CAR‐T and 56% of BsAb patients. Cytokine release syndrome (CRS) occurred in 83% of CAR‐T and 78% of BsAb recipients, while immune effector cell‐associated neurotoxicity syndrome (ICANS) was observed in three CAR‐T patients. Infections of grade ≥3 were reported in 50% of CAR‐T and 44% of BsAb recipients. No exacerbation of graft‐versus‐host disease occurred except in one BsAb recipient. CAR‐T and BsAb therapies appear to be feasible, safe and provide deep and durable responses in MM patients with prior allo‐HCT.
Characteristics of childhood intermittent exotropia with and without DVD
Kramer, Andrea M., Klaehn, Lindsay D. , Hodge, David O. , Mohney, Brian G.

Strabismus | December 6, 2023 | Volume: 31 | Issue: 4 | Pages: 290-292

10.1080/09273972.2023.2286379 | PMID 38054427 Get It

Advanced systemic mastocytosis—Revised classification, new drugs and how we treat
Pardanani, Animesh , Reichard, Kaaren K. , Tefferi, Ayalew

British Journal of Haematology | December 6, 2023 | Volume: 204 | Issue: 2 | Pages: 402-414

10.1111/bjh.19245 | PMID 38054381 Get It

SummaryMastocytosis constitutes the neoplastic proliferation of mast cells and is broadly classified into systemic mastocytosis (SM), cutaneous mastocytosis and mast cell sarcoma. SM is further partitioned into advanced (AdvSM) and non‐advanced (SM‐non‐Adv) subcategories. AdvSM includes aggressive SM (ASM), SM with an associated haematological neoplasm (SM‐AHN) and mast cell leukaemia (MCL). In 2022, two separate expert committees representing the 5th edition of the World Health Organization (WHO5) and the International Consensus (ICC) classification systems submitted revised classification criteria for SM, highlighted by the ICC‐proposed incorporation of mast cell cytomorphology in the diagnostic criteria for MCL and myeloid‐lineage restriction for the AHN component in SM‐AHN. Recent developments in SM also include the introduction of KIT‐targeting tyrosine kinase inhibitors (KITi), including midostaurin and avapritinib, both drugs have shown potent activity in reducing mast cell and mutant KIT burden and alleviating mast cell‐associated organopathy and mediator symptoms; however, their overall impact on survival or superiority over pre‐KITi era treatment options (e.g. cladribine) has not been studied in a controlled setting. In the current review, we provide a summary of recent changes in disease classification and an analysis of recent clinical trials and their impact on our current treatment approach in AdvSM.